Bayer AG fell the most in more than two years after a rival to its Xarelto blood thinner outperformed in a study, prompting analysts to slash their sales estimates for the German drugmaker’s product.
Roche Holding AG halted testing of its most-advanced experimental diabetes drug over safety concerns and said it’s reassessing its research and development program for heart and metabolic diseases.
Novartis AG won the backing of the European Union’s drug regulator for the Bexsero meningitis shot that Chief Executive Officer Joe Jimenez said was key to returning the company’s vaccines division to profitability.
AstraZeneca Plc, the U.K.’s second- biggest drugmaker, may need to change its drug development strategy after setbacks with experimental treatments for cancer and depression, analysts said.
"Merck is some way behind the leading immuno-oncology players and we believe that to gain a foothold will require substantial investment across a wide range of clinical trials in numerous cancer types."
- Alistair Campbell on Nov 17, 2014